Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CMPX with free AI briefings, catalyst countdowns, and dilution alerts.

CMPX · Compass Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$163.1M Cash on Hand
31.5mo Cash Runway
27.1% Short Interest
$5.26 Analyst Target (11)
Follow CMPX by email Get an email when CMPX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CMPX, unsubscribe in one click. Privacy

📣 What CMPX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
COMP360 psilocybin PTSD - Post Traumatic Stress Disorder Phase 2/3 · NCT07570654 Recruiting
Tovecimig (CTX-009) Biliary Tract Cancer Phase 2/3 · NCT05506943 Active not recruiting
Psilocybine Treatment Resistant Depression Phase 3 · NCT05711940 Active not recruiting
Fluorouracil Colorectal Cancer Phase 2 · NCT07662031 Not yet recruiting
Anti-CD137 Agonistic Monoclonal Antibody CTX-471 Glioblastoma Phase 1/2 · NCT07392957 Recruiting
Irinotecan Colorectal Cancer Phase 2 · NCT07662031 Not yet recruiting
CTX-10726 Gastroesophageal Cancer (GC) Phase 1 · NCT07419841 Recruiting
Anti-PD-1/Anti-PD-L1 Bispecific Antibody… Non Small Cell Lung Cancer Phase 1 · NCT06150664 Recruiting

Also used in these trials (approved or third-party drugs, not CMPX's own candidates): Paclitaxel, Cisplatin, Durvalumab, Gemcitabine Hydrochloride, Leucovorin, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CMPX holds $163.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.5M/quarter from operations, an estimated runway of 31.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 20 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CMPX files for a raise →

👥 Who Owns CMPX

Insiders 12.8% Institutions (233 holders) 86.4% Public and other holders 0.8%
HolderTypeShares% of sharesAs of
Tang Capital Management, LLC Institution (13F) 17,990,782 9.99% 2026-09-30
Carl L Gordon
Director · +130,000 options
Insider 15,219,994 8.45% 2025-04-09
ORBIMED ADVISORS LLC
Director, 10% owner
Includes shares also reported by Carl L Gordon, counted once
Insider 15,219,994 8.45% 2025-08-13
Montanova Capital LLC Institution (13F) 14,326,988 7.96% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 9,271,644 5.15% 2025-12-31
Enavate Sciences Gp, LLC Institution (13F) 7,788,150 4.32% 2026-09-30
State Street Corporation Institution (13F) 7,737,938 4.30% 2026-09-30
Palo Alto Investors Lp Institution (13F) 7,148,673 3.97% 2026-09-30
Thomas J. Schuetz
CHIEF EXECUTIVE OFFICER, Director · +3.50M options
Insider 6,603,336 3.67% 2026-02-08
Vanguard Capital Management LLC Institution (13F) 5,994,782 3.33% 2026-09-30
Qube Research & Technologies Ltd Institution (13F) 4,170,894 2.32% 2026-09-30
Barry Shin
CFO · +1.32M options
Insider 525,000 0.29% 2026-01-02

Share count 180,087,915 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-01
filed 2026-10-02
Lerner Neil
Purchase (P) 20,000 $0.92 420,000
2026-09-24
filed 2026-09-25
Lerner Neil
Purchase (P) 2,500 $1.14 400,000
2026-04-29
filed 2026-04-29
Anderman Jonathan
Award (A) 25,000 $1.89 196,000
2026-04-29
filed 2026-04-29
Lerner Neil
Award (A) 15,000 $1.89 397,500
2026-02-08
filed 2026-02-10
Schuetz Thomas J.
Tax withholding (F) 36,687 $6.52 6,603,336

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full CMPX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CMPX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.